Literature DB >> 29140184

Refining the ischemic penumbra with topography.

Tharani Thirugnanachandran1, Henry Ma1, Shaloo Singhal1, Lee-Anne Slater2, Stephen M Davis3, Geoffrey A Donnan4, Thanh Phan1.   

Abstract

It has been 40 years since the ischemic penumbra was first conceptualized through work on animal models. The topography of penumbra has been portrayed as an infarcted core surrounded by penumbral tissue and an extreme rim of oligemic tissue. This picture has been used in many review articles and textbooks before the advent of modern imaging. In this paper, we review our understanding of the topography of the ischemic penumbra from the initial experimental animal models to current developments with neuroimaging which have helped to further define the temporal and spatial evolution of the penumbra and refine our knowledge. The concept of the penumbra has been successfully applied in clinical trials of endovascular therapies with a time window as long as 24 h from onset. Further, there are reports of "good" outcome even in patients with a large ischemic core. This latter observation of good outcome despite having a large core requires an understanding of the topography of the penumbra and the function of the infarcted regions. It is proposed that future research in this area takes departure from a time-dependent approach to a more individualized tissue and location-based approach.

Entities:  

Keywords:  Penumbra; diffusion-weighted imaging; neuroimaging; oligemia ischemic stroke; perfusion-weighted imaging; reperfusion; topography

Mesh:

Year:  2017        PMID: 29140184     DOI: 10.1177/1747493017743056

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  8 in total

1.  Bexarotene Attenuates Focal Cerebral Ischemia-Reperfusion Injury via the Suppression of JNK/Caspase-3 Signaling Pathway.

Authors:  Hailin Liu; Shengwei Liu; Xiaocui Tian; Qian Wang; Jiangyan Rao; Yucun Wang; Fei Xiang; Hang Zheng; Lu Xu; Zhi Dong
Journal:  Neurochem Res       Date:  2019-11-03       Impact factor: 3.996

2.  Evaluation of T2-FLAIR combined with ASL on the collateral circulation of acute ischemic stroke.

Authors:  Miaona Zhang; Qiang Shi; Yun Yue; Minfeng Zhang; Lei Zhao; Chengxin Yan
Journal:  Neurol Sci       Date:  2022-04-06       Impact factor: 3.830

Review 3.  On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer's Disease.

Authors:  Jan Kriska; Zuzana Hermanova; Tomas Knotek; Jana Tureckova; Miroslava Anderova
Journal:  Int J Mol Sci       Date:  2021-09-07       Impact factor: 6.208

Review 4.  Hydroxyethylstarch revisited for acute brain injury treatment.

Authors:  Martin A Schick; Malgorzata Burek; Carola Y Förster; Michiaki Nagai; Christian Wunder; Winfried Neuhaus
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

5.  Microglial-specific depletion of TAK1 is neuroprotective in the acute phase after ischemic stroke.

Authors:  Thomas Zeyen; Rozina Noristani; Shahin Habib; Ole Heinisch; Alexander Slowik; Michael Huber; Jörg B Schulz; Arno Reich; Pardes Habib
Journal:  J Mol Med (Berl)       Date:  2020-05-07       Impact factor: 4.599

Review 6.  Tissue Acidosis Associated with Ischemic Stroke to Guide Neuroprotective Drug Delivery.

Authors:  Orsolya M Tóth; Ákos Menyhárt; Rita Frank; Dóra Hantosi; Eszter Farkas; Ferenc Bari
Journal:  Biology (Basel)       Date:  2020-12-11

7.  Deep Learning-Based Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Ischemic Penumbra in Early Cerebral Infarction.

Authors:  Hui Sheng; Xueling Wang; Meiping Jiang; Zhongsheng Zhang
Journal:  Contrast Media Mol Imaging       Date:  2022-02-28       Impact factor: 3.161

8.  Neuroprotective Effects of Isosteviol Sodium in Murine Brain Capillary Cerebellar Endothelial Cells (cerebEND) After Hypoxia.

Authors:  Nils Rösing; Ellaine Salvador; Paul Güntzel; Christoph Kempe; Malgorzata Burek; Ulrike Holzgrabe; Vladimir Soukhoroukov; Christian Wunder; Carola Förster
Journal:  Front Cell Neurosci       Date:  2020-10-28       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.